Literature DB >> 35624355

NKCC1 to KCC2 mRNA Ratio in Schizophrenia and Its Psychopathology: a Case-Control Study.

Hoorie Mohaghghegh1, Esmaeil Shahsavand Ananloo2,3,4,5, Mahmoudreza Hadjighasem6,7, Morteza Karimipour8, Shiva Hashemizadeh9, Seyyed Ali Ahmadi Abhari10,11.   

Abstract

Schizophrenia (SCZ) is a debilitating, destructive, and chronic mental disorder and affects approximately one percent of the human population. Diagnosis in psychiatry is based on the patient's descriptions of his/her symptoms, interviewer's observations, history of disorder over time, and response to treatment. All of these data measure phenotype-based functions. But it appears that accurate diagnosis of such a complex disorder must be based on valid and reliable factors. In the present study, gene selection was based on the possible role of γ-aminobutyric acid (GABA) in psychopathology of SCZ and expression in blood. We evaluated the association of Na+-K+-Cl- co-transporter 1 (NKCC1) and K+-Cl- co-transporter 2 (KCC2) genes' messenger ribonucleic acid (mRNA) levels, and also the NKCC1/KCC2 ratio with positive and negative syndrome scale (PANSS) and brief psychiatric rating scale (BPRS) scores in an SCZ group. By using real-time PCR (RT-PCR), the present study is the first attempt to explore levels of NKCC1 and KCC2 expression at mRNA level and their relative expression in human peripheral blood of patients with SCZ. Our results showed that the NKCC1 to KCC2 mRNA ratio is significantly increased (but based on the delta cycle of threshold [∆Ct] is significantly lower) in the total sample of cases rather than controls (p = 0.045) and also higher in male sample cases rather than male controls (p = 0.016). In female samples, we found a trend toward a significant effect between the case and control participants (p = 0.075). We also found statistically significant association between mRNA of NKCC1 and KCC2 genes and NKCC1/KCC2 mRNA ratio with the positive and negative syndrome scale (PANSS) and brief psychiatric rating scale (BPRS) scores.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Gene; KCC2; NKCC1; PANSS; Schizophrenia; mRNA

Mesh:

Substances:

Year:  2022        PMID: 35624355     DOI: 10.1007/s12031-021-01879-7

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   2.866


  36 in total

1.  Anomalous levels of Cl- transporters cause a decrease of GABAergic inhibition in human peritumoral epileptic cortex.

Authors:  Luca Conti; Eleonora Palma; Cristina Roseti; Clotilde Lauro; Raffaela Cipriani; Marjolein de Groot; Eleonora Aronica; Cristina Limatola
Journal:  Epilepsia       Date:  2011-06-02       Impact factor: 5.864

2.  Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia.

Authors:  Nikola A Bowden; Judith Weidenhofer; Rodney J Scott; Ulrich Schall; Juanita Todd; Patricia T Michie; Paul A Tooney
Journal:  Schizophr Res       Date:  2006-01-18       Impact factor: 4.939

3.  Altered expression of regulators of the cortical chloride transporters NKCC1 and KCC2 in schizophrenia.

Authors:  Dominique Arion; David A Lewis
Journal:  Arch Gen Psychiatry       Date:  2010-09-06

Review 4.  Excitatory action of GABA on immature neurons is not due to absence of ketone bodies metabolites or other energy substrates.

Authors:  Yehezkel Ben-Ari; Roman Tyzio; Astrid Nehlig
Journal:  Epilepsia       Date:  2011-06-21       Impact factor: 5.864

Review 5.  Handedness in schizophrenia: a quantitative review of evidence.

Authors:  M Dragovic; G Hammond
Journal:  Acta Psychiatr Scand       Date:  2005-06       Impact factor: 6.392

Review 6.  Genomics and pharmacogenomics of schizophrenia.

Authors:  Ramón Cacabelos; Rocío Martínez-Bouza
Journal:  CNS Neurosci Ther       Date:  2010-08-16       Impact factor: 5.243

Review 7.  α2-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders.

Authors:  Elif Engin; Jing Liu; Uwe Rudolph
Journal:  Pharmacol Ther       Date:  2012-08-18       Impact factor: 12.310

8.  Measuring pathology using the PANSS across diagnoses: Inconsistency of the positive symptom domain across schizophrenia, schizoaffective, and bipolar disorder.

Authors:  Ariana E Anderson; Maxwell Mansolf; Steven P Reise; Adam Savitz; Giacomo Salvadore; Qingqin Li; Robert M Bilder
Journal:  Psychiatry Res       Date:  2017-08-16       Impact factor: 3.222

9.  Association of transcription factor 4 (TCF4) gene mRNA level with schizophrenia, its psychopathology, intelligence and cognitive impairments.

Authors:  Fatemeh Alizadeh; Javad Tavakkoly-Bazzaz; Ali Bozorgmehr; Asa'ad Azarnezhad; Mina Tabrizi; Esmaeil Shahsavand Ananloo
Journal:  J Neurogenet       Date:  2017-11-06       Impact factor: 1.250

10.  Genome-wide association study identifies 48 common genetic variants associated with handedness.

Authors:  Gabriel Cuellar-Partida; Joyce Y Tung; Nicholas Eriksson; Eva Albrecht; Fazil Aliev; Ole A Andreassen; Inês Barroso; Jacques S Beckmann; Marco P Boks; Dorret I Boomsma; Heather A Boyd; Monique M B Breteler; Harry Campbell; Daniel I Chasman; Lynn F Cherkas; Gail Davies; Eco J C de Geus; Ian J Deary; Panos Deloukas; Danielle M Dick; David L Duffy; Johan G Eriksson; Tõnu Esko; Bjarke Feenstra; Frank Geller; Christian Gieger; Ina Giegling; Scott D Gordon; Jiali Han; Thomas F Hansen; Annette M Hartmann; Caroline Hayward; Kauko Heikkilä; Andrew A Hicks; Joel N Hirschhorn; Jouke-Jan Hottenga; Jennifer E Huffman; Liang-Dar Hwang; M Arfan Ikram; Jaakko Kaprio; John P Kemp; Kay-Tee Khaw; Norman Klopp; Bettina Konte; Zoltan Kutalik; Jari Lahti; Xin Li; Ruth J F Loos; Michelle Luciano; Sigurdur H Magnusson; Massimo Mangino; Pedro Marques-Vidal; Nicholas G Martin; Wendy L McArdle; Mark I McCarthy; Carolina Medina-Gomez; Mads Melbye; Scott A Melville; Andres Metspalu; Lili Milani; Vincent Mooser; Mari Nelis; Dale R Nyholt; Kevin S O'Connell; Roel A Ophoff; Cameron Palmer; Aarno Palotie; Teemu Palviainen; Guillaume Pare; Lavinia Paternoster; Leena Peltonen; Brenda W J H Penninx; Ozren Polasek; Peter P Pramstaller; Inga Prokopenko; Katri Raikkonen; Samuli Ripatti; Fernando Rivadeneira; Igor Rudan; Dan Rujescu; Johannes H Smit; George Davey Smith; Jordan W Smoller; Nicole Soranzo; Tim D Spector; Beate St Pourcain; John M Starr; Hreinn Stefánsson; Stacy Steinberg; Maris Teder-Laving; Gudmar Thorleifsson; Kári Stefánsson; Nicholas J Timpson; André G Uitterlinden; Cornelia M van Duijn; Frank J A van Rooij; Jaqueline M Vink; Peter Vollenweider; Eero Vuoksimaa; Gérard Waeber; Nicholas J Wareham; Nicole Warrington; Dawn Waterworth; Thomas Werge; H-Erich Wichmann; Elisabeth Widen; Gonneke Willemsen; Alan F Wright; Margaret J Wright; Mousheng Xu; Jing Hua Zhao; Peter Kraft; David A Hinds; Cecilia M Lindgren; Reedik Mägi; Benjamin M Neale; David M Evans; Sarah E Medland
Journal:  Nat Hum Behav       Date:  2020-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.